Cancer Care Kenya's Revenue Nearly Doubles to Sh1 Billion in Fiscal 2026

Cancer Care Kenya, the organisation behind the well-known HCG Cancer Centre in Nairobi, has posted a remarkable financial performance for the fiscal year ending March 31, 2026. The facility saw its revenue surge by 71 percent to Sh1.01 billion, a sharp jump from the Sh593 million recorded in the previous financial year — marking one of the strongest growth runs by a dedicated cancer care provider in the country.

The growth places the Nairobi-based specialist oncology centre in a strong position within the broader East African healthcare landscape. Notably, Cancer Care Kenya contributes roughly 5 percent of the total annual revenue of its parent company, HealthCare Global Enterprises Ltd — a meaningful share for a single facility operating in the Kenyan market.

The momentum did not fade even as the financial year drew to a close. In the final quarter alone, the centre's revenue grew 39 percent year-on-year, climbing to Sh269 million from Sh193 million over the same period the year before. That kind of consistent late-year acceleration suggests the growth reflects a lasting structural shift rather than a temporary uptick.

Management credited the strong showing to a combination of factors: tighter operating discipline, a rising number of patients seeking treatment at the facility, and an expanded portfolio of cancer services now on offer. As cancer rates continue to increase across Kenya and the wider East African region, more patients appear to be choosing local specialist centres over the expensive and logistically difficult option of seeking care abroad.

HCG Cancer Centre in Nairobi offers a comprehensive suite of oncology services, ranging from early-stage diagnosis and chemotherapy to radiotherapy and more advanced treatment protocols. That breadth of in-country capability matters enormously for Kenyan patients who have historically had few options short of travelling to India, South Africa, or Europe to access comparable care.

Cancer Care Kenya operates under HealthCare Global Enterprises Ltd, which runs a wider international healthcare portfolio. One of its other key assets is the Milann fertility business in India. The parent company has confirmed plans to divest Milann, with the sale expected to be finalised during the first quarter of 2027.

The strong revenue numbers from Cancer Care Kenya point to a growing appetite for quality, affordable oncology services within Kenya — and demonstrate that building specialist medical infrastructure locally can be both commercially viable and a genuine lifeline for thousands of patients facing one of the country's most serious public health challenges.